GLP-1 TirzepatideRx

All-in monthly price at 10 mg — medication plus any membership fee

Home Compare

Tirzepatide Programs, Head to Head

Every pairing priced at all six dose tiers, with the twelve-month difference stated plainly.

Written by Eduard CristeaMedically reviewed by Dr. A. Goher, MDUpdated 2026-08-05Prices verified 2026-08-05

Each comparison prices both programs across the full titration ladder and states the twelve-month difference on a realistic escalation curve. Where one program is flat-rate and the other scales with dose, the gap usually inverts somewhere between 5 mg and 10 mg — the comparison says exactly where.

Also compare

Primary sources

Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.

  1. ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
  2. FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
  3. FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
  4. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
  5. The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.